NCT04943484Recruiting
ICG (Indocyanine Green) Imaging Fluorescence Technology in Surgical Treatment of Advanced Gastric Cancer
[The iGreenGO Study]. Investigation About the Clinical Value of Indocyanine Green Imaging Fluorescence (NIR/ICG) Technology as a Modifier of Surgeon's Conduct During Curative Treatment of Advanced Gastric Cancer. Study Protocol for a Western, Observational, Prospective, Multicentric Study
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
The iGreenGO Study aims to investigate whether the intraoperative application of NIR/ICG technology is associated with a change in the surgical conduct (CSC) during curative-intent gastrectomy with D2 lymphadenectomy in a cohort of Western patients affected by AGC. The preoperative clinical variables potentially associated with CSC will be also investigated
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 360 (estimated)
- First submitted
- 21 Jun 2021
- Start date
- 1 Jan 2022
- Primary completion date
- 31 Aug 2024
- Lead sponsor
- Niguarda Hospital
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT04943484
What you commit to
- Study type: Observational
- Planned participants: 360
- From 1 Jan 2022 to the primary completion date, 31 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of previous upper abdominal surgery (laparoscopic cholecystectomy will be allowed)
- History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection
- History of previous neoadjuvant chemotherapy (except perioperative chemotherapy for gastric cancer) or radiotherapy
Other illness
- History of allergy to iodine agents
- Cancer located at the esophago-gastric junction (Siewert I, II, III tumors 29)
Other
- Women during pregnancy or breast-feeding
- Patients candidates to transthoracic esophagectomy, transhiatal extended gastrectomy or proximal gastrectomy
Who the study is looking for
- Age ≥ 18 years old
- Preoperative histologically proven adenocarcinoma of the upper, middle or lower part of the stomach.
- Advanced disease (Staged cT2-T4a, N0-3;M0 according to 8th edition of the AJCC TNM Staging System) at diagnosis, in which resection can be safely achieved by distal or total gastrectomy with D2 lymphadenectomy via a minimally invasive (laparoscopic or robotic) approach, either as first treatment or after neoadjuvant treatment
- No distant metastasis, no direct invasion of pancreas, spleen or other organs nearby in the preoperative and intraoperative examinations
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ASST GOM Niguarda Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.